Venclexta (venetoclax)
Venclexta (Venetoclax) is an oral targeted therapy used to treat certain blood cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). It works by inhibiting the B-cell lymphoma-2 (BCL-2) protein, helping cancer cells undergo programmed cell death and reducing disease progression.
Verzenio (Abemaciclib)
Verzenio (Abemaciclib) is an oral targeted therapy used primarily for the treatment of certain types of hormone receptor (HR)-positive, HER2-negative breast cancer. It works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), proteins that promote cancer cell growth and division, helping to slow disease progression and improve treatment outcomes.
Xgeva (denosumab)
Xgeva (Denosumab) is a targeted monoclonal antibody used to prevent skeletal-related complications in patients with cancers that have spread to the bones and to treat certain bone-related conditions. It works by inhibiting RANKL, a protein involved in bone breakdown, helping to strengthen bones and reduce the risk of fractures and other skeletal complications.
Xtandi (Enzalutamide)
Yervoy (ipilimumab)
Yervoy (Ipilimumab) is an advanced immunotherapy medicine used to treat several types of cancer, including melanoma, kidney cancer, colorectal cancer, and lung cancer. As a CTLA-4 inhibitor, it works by enhancing the body's immune response, helping immune cells recognize and attack cancer cells more effectively.
